Delayed
Börse Stuttgart
|
5-day change
|
1st Jan Change
|
- EUR
|
-.--%
|
|
-1.36%
|
+15.08%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
267,779
|
264,244
|
306,810
|
259,166
|
197,073
|
200,899
|
-
|
-
|
Enterprise Value (EV)
1 |
270,284
|
266,126
|
324,977
|
274,750
|
215,772
|
215,173
|
210,071
|
204,121
|
P/E ratio
|
20.1
x
|
18.7
x
|
23.4
x
|
18.9
x
|
17.1
x
|
14.6
x
|
13.3
x
|
12.3
x
|
Yield
|
2.87%
|
2.94%
|
2.45%
|
3.27%
|
3.93%
|
3.94%
|
4.05%
|
4.15%
|
Capitalization / Revenue
|
4.36
x
|
4.53
x
|
4.89
x
|
4.1
x
|
3.36
x
|
3.31
x
|
3.14
x
|
3.01
x
|
EV / Revenue
|
4.4
x
|
4.56
x
|
5.17
x
|
4.34
x
|
3.67
x
|
3.55
x
|
3.28
x
|
3.06
x
|
EV / EBITDA
|
10.6
x
|
11
x
|
13.2
x
|
11
x
|
9.82
x
|
9.45
x
|
8.56
x
|
7.91
x
|
EV / FCF
|
16.1
x
|
24.3
x
|
20.7
x
|
21.1
x
|
19.1
x
|
15.9
x
|
14.3
x
|
13.3
x
|
FCF Yield
|
6.2%
|
4.11%
|
4.83%
|
4.75%
|
5.23%
|
6.27%
|
7%
|
7.54%
|
Price to Book
|
8.28
x
|
7.27
x
|
13.2
x
|
8.29
x
|
5.91
x
|
5.65
x
|
4.72
x
|
3.99
x
|
Nbr of stocks (in thousands)
|
856,061
|
854,642
|
800,952
|
854,579
|
798,652
|
797,242
|
-
|
-
|
Reference price
2 |
314.0
|
309.0
|
379.1
|
290.5
|
244.5
|
248.5
|
248.5
|
248.5
|
Announcement Date
|
30/01/20
|
04/02/21
|
03/02/22
|
02/02/23
|
01/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
61,466
|
58,323
|
62,801
|
63,281
|
58,716
|
60,642
|
63,971
|
66,686
|
EBITDA
1 |
25,419
|
24,281
|
24,692
|
25,015
|
21,976
|
22,781
|
24,548
|
25,797
|
EBIT
1 |
22,479
|
21,536
|
21,897
|
22,173
|
19,240
|
20,096
|
21,816
|
22,908
|
Operating Margin
|
36.57%
|
36.93%
|
34.87%
|
35.04%
|
32.77%
|
33.14%
|
34.1%
|
34.35%
|
Earnings before Tax (EBT)
1 |
16,614
|
17,965
|
17,398
|
16,327
|
14,079
|
17,825
|
19,612
|
20,763
|
Net income
1 |
13,497
|
14,295
|
13,930
|
12,421
|
11,498
|
13,288
|
14,733
|
15,739
|
Net margin
|
21.96%
|
24.51%
|
22.18%
|
19.63%
|
19.58%
|
21.91%
|
23.03%
|
23.6%
|
EPS
2 |
15.62
|
16.52
|
16.20
|
15.37
|
14.31
|
16.97
|
18.72
|
20.18
|
Free Cash Flow
1 |
16,764
|
10,943
|
15,691
|
13,041
|
11,288
|
13,500
|
14,699
|
15,387
|
FCF margin
|
27.27%
|
18.76%
|
24.99%
|
20.61%
|
19.22%
|
22.26%
|
22.98%
|
23.07%
|
FCF Conversion (EBITDA)
|
65.95%
|
45.07%
|
63.55%
|
52.13%
|
51.37%
|
59.26%
|
59.88%
|
59.65%
|
FCF Conversion (Net income)
|
124.21%
|
76.55%
|
112.64%
|
104.99%
|
98.17%
|
101.59%
|
99.77%
|
97.77%
|
Dividend per Share
2 |
9.000
|
9.100
|
9.300
|
9.500
|
9.600
|
9.787
|
10.06
|
10.32
|
Announcement Date
|
30/01/20
|
04/02/21
|
03/02/22
|
02/02/23
|
01/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 Q3
|
2021 Q4
|
2021 S2
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 S2
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2024 S2
|
2025 Q1
|
2025 S1
|
2025 S2
|
---|
Net sales
1 |
30,997
|
29,281
|
29,042
|
30,713
|
15,971
|
16,117
|
32,088
|
16,445
|
15,850
|
32,295
|
14,742
|
16,244
|
30,986
|
15,322
|
14,457
|
29,779
|
14,274
|
28,937
|
14,399
|
14,540
|
29,895
|
14,690
|
15,015
|
30,814
|
15,320
|
30,630
|
30,615
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
10,116
|
11,766
|
9,770
|
11,652
|
-
|
-
|
10,245
|
-
|
-
|
12,668
|
-
|
-
|
9,505
|
-
|
-
|
10,911
|
-
|
8,329
|
-
|
-
|
10,487
|
-
|
-
|
9,641
|
-
|
-
|
-
|
Operating Margin
|
32.64%
|
40.18%
|
33.64%
|
37.94%
|
-
|
-
|
31.93%
|
-
|
-
|
39.23%
|
-
|
-
|
30.68%
|
-
|
-
|
36.64%
|
-
|
28.78%
|
-
|
-
|
35.08%
|
-
|
-
|
31.29%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
6,260
|
10,181
|
7,784
|
9,887
|
-
|
-
|
7,511
|
-
|
-
|
10,985
|
-
|
-
|
5,342
|
-
|
-
|
9,174
|
-
|
4,905
|
-
|
-
|
8,930
|
-
|
-
|
9,368
|
-
|
-
|
-
|
Net income
|
4,878
|
8,079
|
6,216
|
7,803
|
-
|
-
|
6,127
|
-
|
-
|
8,530
|
-
|
-
|
3,891
|
-
|
-
|
7,137
|
-
|
4,361
|
-
|
-
|
6,629
|
-
|
-
|
7,071
|
-
|
-
|
-
|
Net margin
|
15.74%
|
27.59%
|
21.4%
|
25.41%
|
-
|
-
|
19.09%
|
-
|
-
|
26.41%
|
-
|
-
|
12.56%
|
-
|
-
|
23.97%
|
-
|
15.07%
|
-
|
-
|
22.17%
|
-
|
-
|
22.95%
|
-
|
-
|
-
|
EPS
|
5.630
|
9.320
|
7.200
|
9.050
|
-
|
-
|
7.150
|
-
|
-
|
10.54
|
-
|
-
|
4.830
|
-
|
-
|
8.870
|
-
|
5.440
|
-
|
-
|
8.250
|
-
|
-
|
8.820
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/01/20
|
23/07/20
|
04/02/21
|
22/07/21
|
20/10/21
|
03/02/22
|
03/02/22
|
25/04/22
|
21/07/22
|
21/07/22
|
18/10/22
|
02/02/23
|
02/02/23
|
27/04/23
|
27/07/23
|
27/07/23
|
01/11/23
|
01/02/24
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
2,505
|
1,882
|
18,167
|
15,584
|
18,699
|
14,273
|
9,172
|
3,222
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.0985
x
|
0.0775
x
|
0.7357
x
|
0.623
x
|
0.8509
x
|
0.6265
x
|
0.3736
x
|
0.1249
x
|
Free Cash Flow
1 |
16,764
|
10,943
|
15,691
|
13,041
|
11,288
|
13,500
|
14,699
|
15,387
|
ROE (net income / shareholders' equity)
|
57.7%
|
48%
|
56%
|
62.5%
|
45.7%
|
43.7%
|
40.5%
|
36.4%
|
ROA (Net income/ Total Assets)
|
21.6%
|
19.6%
|
19.1%
|
18.2%
|
16.7%
|
14.6%
|
14.9%
|
14.7%
|
Assets
1 |
62,621
|
72,966
|
72,951
|
68,337
|
68,793
|
91,167
|
98,657
|
107,377
|
Book Value Per Share
2 |
37.90
|
42.50
|
28.80
|
35.00
|
41.40
|
44.00
|
52.60
|
62.30
|
Cash Flow per Share
2 |
25.90
|
21.50
|
24.40
|
22.80
|
20.00
|
20.10
|
21.50
|
23.70
|
Capex
1 |
3,503
|
3,528
|
3,693
|
3,449
|
3,742
|
3,735
|
3,909
|
4,065
|
Capex / Sales
|
5.7%
|
6.05%
|
5.88%
|
5.45%
|
6.37%
|
6.16%
|
6.11%
|
6.09%
|
Announcement Date
|
30/01/20
|
04/02/21
|
03/02/22
|
02/02/23
|
01/02/24
|
-
|
-
|
-
|
Last Close Price
248.5
CHF Average target price
278.3
CHF Spread / Average Target +11.98% Consensus |
1st Jan change
|
Capi.
|
---|
| +55.55% | 823B | | +42.31% | 641B | | -6.83% | 352B | | +17.15% | 324B | | +7.09% | 301B | | +14.02% | 241B | | +13.66% | 218B | | +7.87% | 167B | | -3.33% | 160B |
Other Pharmaceuticals
|